
Resdac 0.5mg Injection
Marketer
Rescuers Life Sciences Ltd
Salt Composition
Dactinomycin (0.5mg)
Overview Resdac 0.5mg Injection
Dactinomycin 0.5mg Injection is indicated for various cancers, including testicular, gestational trophoblastic, Wilms' tumor, and Ewing's sarcoma. Its mechanism involves disrupting cancerous cell proliferation, leading to their destruction. Administered under medical supervision, self-medication is strictly prohibited. Treatment may involve single administration or combination therapy, with dosage and frequency determined by your oncologist based on your specific condition and subject to adjustment. Precise adherence to the prescribed regimen is crucial; incorrect usage or overdose can result in severe adverse effects. Therapeutic benefits may not be immediately apparent, potentially taking weeks or months to manifest; discontinuation should only occur upon physician instruction. Alcohol consumption should be avoided due to the potential for increased liver damage. Common side effects comprise nausea, vomiting, mucositis, and anorexia; persistent or worsening symptoms necessitate medical consultation. Serious adverse events are possible; this potent medication may impair immune function and affect blood, liver, or kidney health, necessitating routine blood monitoring. Prior to commencement, disclose any existing liver or kidney conditions, or concurrent use of anti-infectives or other medications, as drug interactions are possible. Use during pregnancy or lactation is contraindicated due to potential harm to the fetus or infant. Contraception should be employed by both partners for several months post-treatment cessation. Pre- and ongoing treatment will involve regular blood tests and physical examinations.
Primary Ingredients of Resdac 0.5mg Injection
No text provided. Please provide the text you want me to rephrase.
Uses of Resdac 0.5mg Injection
Malignancies affecting the testes, kidneys in children, gestational tissues, and bone
Major Benefits of Resdac 0.5mg Injection:
The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Resdac 0.5mg Injection:
- Nausea
- Vomiting
- Loss of appetite
- Glossitis (tongue inflammation)
- Lip inflammation
- Diarrhea
- Inflammation of the rectum
- Low blood platelets
How to use Resdac 0.5mg Injection:
Administering this medication will be handled by your physician or registered nurse; self-medication is strictly prohibited.
How Resdac 0.5mg Injection works:
Resdac 0.5mg Injection is a cancer treatment that disrupts the DNA of malignant cells, thereby inhibiting their proliferation and expansion.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Resdac 0.5mg Injection may pose safety risks; seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Administering Resdac 0.5mg Injection during pregnancy is contraindicated due to confirmed risk to the fetus. Exceptions may exist in critical circumstances where a physician deems the potential benefits outweigh the hazards. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Administering Resdac 0.5mg Injection while breastfeeding is likely inadvisable. Preliminary human evidence indicates potential drug transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Resdac 0.5mg Injection on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Resdac 0.5mg Injection appears safe for individuals with impaired renal function. Preliminary evidence indicates dose modification may be unnecessary. Physician consultation is recommended.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding Resdac 0.5mg Injection's use in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Resdac 0.5mg Injection :
NA
Facts to Know About Resdac 0.5mg Injection
| Label | Value |
|---|---|
| Chemical Type | Cancer-Fighting Antibiotics |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavior Class | Cytotoxic alkaloids |
